. b-arrestin-dependent signaling events have typically been thought to be mostly 'independent' of G proteins. Synthetic ligands capable of selectively inducing b-arrestin recruitment and signaling have been identified and described for several GPCRs and are referred to as b-arrestin-biased ligands [4, 5] . Two recent studies from Wang et al. [6, 7] now demonstrate that an interplay between Gai and b-arrestins is actually important for the phosphorylation of ERK1/2 MAP kinase and transactivation of epidermal growth factor receptor (EGFR) downstream of the b1-adrenergic receptor (b1AR) and the angiotensin II type 1a receptor (AT1aR) ( Figure 1 ) [6, 7] . Carvedilol is a small-molecule ligand of the b-adrenergic receptors b1AR and b2AR. It was originally classified as an antagonist or inverse agonist because it lowers the basal level of cAMP in bARexpressing cells produced through the coupling of these receptors with the stimulatory G protein Gas. Recent studies, however, have reported that carvedilol can induce the phosphorylation of ERK1/2 MAP kinase in a b-arrestindependent fashion, independent of Gas, and hence categorized it as a b-arrestinbiased ligand [8, 9] . Inspired by the recent visualization of GPCR supercomplexes, which consist of heterotrimeric G proteins and b-arrestins simultaneously bound to activated receptors [10] , Wang et al. [6] set out to probe the possible contribution of the inhibitory G protein Gai in carvedilol-stimulated b1AR signaling. Interestingly, they discovered that carvedilol-induced phosphorylation of ERK1/2 MAP kinase is robustly sensitive to inhibition of Gai by pertussis toxin (PTX) not only in cultured cells but also in tissue lysate prepared from mice hearts. Along the same line, CRISPR-Cas9-mediated removal of Gai from b1AR-expressing cells results in complete ablation of carvedilol-induced ERK1/2 phosphorylation [6] . Interestingly, carvedilol stimulation leads not only to recruitment of Gai to b1AR but also to its activation, as measured by a conformationally selective antibody. Recruitment of Gai is a unique feature of carvedilol because a set of other beta-blockers, or even full agonists such as epinephrine and isoproterenol, fail to exert a similar effect [6] . Moreover, carvedilol-induced internalization of EGFR in b1AR-expressing cells is also sensitive to PTX treatment, suggesting the requirement of functional Gai for this process. Most interestingly, this study recapitulates the absolute requirement for b-arrestins as well as for carvedilol-induced phosphorylation of ERK1/2 MAP kinase and EGFR internalization. Therefore, both Gai and b-arrestins are essential for carvedilolinduced b1AR signaling, suggesting an interplay between these two effectors that goes against the previous notion of complete G-protein independence. In fact, some previous studies have indicated that an interplay of Gai and b-arrestins might exist for Gai-coupled receptors because agonist-induced phosphorylation of ERK1/2 MAP kinase is robustly sensitive to either PTX treatment or b-arrestin knockdown [11] . However, from the study by Wang et al. [6] it seems that b1AR, a receptor that is predominantly Gas coupled, can switch its coupling to Gai in response to a particular ligand, i.e. carvedilol. Yet another striking finding in this study is the different effects of carvedilol on the two subtypes of bARs, i.e. b1AR and b2AR. In contrast with b1AR, carvedilol-induced phosphorylation of ERK1/2 MAP kinase downstream of b2AR is not sensitive to either PTX or CRISPR-Cas9-mediated removal of Gai. Moreover, carvedilol does not trigger detectable recruitment of Gai to b2AR, suggesting the Gai independence of ERK1/2 phosphorylation downstream of b2AR. This interesting mechanistic difference between the signaling of two subtypes of the same receptor in response to the same ligand underscores the level of finetuning that is intricately built in this family of receptors.
So, what could be the possible mechanism of this interplay between Gai and b-arrestins? Contrary to the original two-state conformational model of GPCRs, where the receptors adopt either an inactive or an active conformation, the current framework now involves a broad conformational landscape sampled by GPCRs. It has been proposed and experimentally documented that specific ligands with different functional efficacies stabilize distinct receptor conformations [12] . These distinct receptor conformations are then recognized by downstream effectors, such as G proteins or b-arrestins, and result in corresponding functional outcomes [13] . Moreover, the interaction of downstream effectors can further fine-tune receptor conformations in an allosteric fashion [14] . In this conceptual framework, it is possible that carvedilol stabilizes a unique b1AR conformation that is competent for the recruitment of both Gai and b-arrestins. This is analogous to the previously mentioned b2AR supercomplexes, in which activated and phosphorylated receptors can simultaneously accommodate both Gas and b-arrestins [10, 15] . Using a FRET-based intramolecular conformational sensor, Wang et al. [6] demonstrate that the overall conformation of carvedilol-bound b1AR is distinct from that of isoproterenol-bound b1AR. Moreover, the conformational signature induced by carvedilol is significantly sensitive to PTX treatment (i.e. Gai inhibition), suggesting a critical contribution of the effector (Gai in this case) in allosterically fine-tuning receptor conformation.
In addition to bARs, the angiotensin II type 1a receptor (AT1aR), which primarily couples to the Gaq subtype of G proteins, has been one the most widely used systems to study biased signaling and to decipher the mechanistic basis of this phenomenon. A number of modified peptides based on the endogenous ligand angiotensin II have been synthesized and characterized to identify b-arrestinbiased ligands. In addition, osmotic stretch of AT1aR-expressing cells has also been documented to result in b-arrestin-dependent ERK1/2 phosphorylation in the absence of any detectable Gaq coupling [16] . Here, osmotic stretch serves as a surrogate for the mechanical activation of AT1aR. Wang et al. [6] now demonstrate not only that osmotic stretch results in Gai coupling to AT1aR, but also that functional Gai is essential for b-arrestin 2 recruitment to the receptor [7] . Similar to the b1AR system discussed above, EGFR transactivation and internalization as well as ERK1/2 phosphorylation in AT1aR-expressing cells upon osmotic stretch require both functional Gai and b-arrestins. Interestingly, however, b-arrestin recruitment, EGFR transactivation and ERK1/2 phosphorylation induced by peptidebased b-arrestin-biased AT1aR ligands (TRV023 or TRV026) do not require Gai coupling to the receptor [7] . These observations suggest that, even for the same GPCR, the mechanistic framework utilized by different types of ligands or stimuli may differ significantly in the context of biased signaling. It is also worth mentioning here that a previous study has reported the coupling of AT1aR to Gai when stimulated with yet another peptidebased ligand, referred to as SII, originally described as a completely b-arrestinbiased ligand [17] .
As if this much complexity was not enough, the plot thickens even further. Another recent study by Grundmann et al. [18] has used a CRISPR-Cas9-based approach combined with PTX treatment to eliminate the entire subset of functional Ga proteins (Gas, Gaolf, Gaq/11 and Ga12/13 by CRISPR-Cas9, and Gai by PTX). They report that, under these conditions, although agonist-induced b-arrestin recruitment is preserved, phosphorylation of ERK1/2 is completely ablated. On one hand, this line of evidence suggests that Ga proteins are the major driver of ERK1/2 phosphorylation, but, on the other, it also supports the existence of a more intricate interplay between G proteins and b-arrestins in GPCR signaling.
It is becoming increasingly more evident that a holistic framework of receptor-effector coupling should be applied to assess the contribution of specific effectors in GPCR signaling and to define the properties of biased ligands with better accuracy. The emerging paradigms of G-protein subtype selectivity displayed by some ligands, functional divergence of b-arrestins 1 and 2, distinct receptor-effector conformations coupled to specific functional outcomes, and cell/tissuespecific relative balance of GPCR effectors reveal the finer details of GPCR signaling and paint a very complicated and intricate picture [15, 19, 20] . These recent discoveries clearly warrant a more inclusive and comprehensive analysis of the signaling profiles of new and existing GPCR ligands, especially in the light of recent interest in designing novel GPCR therapeutics based on biased ligands.
